Jazz Pharma to Pay $145 Million to Settle Narcolepsy Drug Antitrust Case

Jazz Pharmaceuticals JAZZ.O said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in the U.S., is used for the …